Cytokinetics (NASDAQ:CYTK) EVP Sells $702,400.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $70.24, for a total value of $702,400.00. Following the transaction, the executive vice president directly owned 58,555 shares of the company’s stock, valued at $4,112,903.20. The trade was a 14.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Callos also recently made the following trade(s):

• On Thursday, July 30th, Andrew Callos sold 14,000 shares of Cytokinetics stock. The stock was sold at an average price of $79.88, for a total transaction of $1,118,320.00.
• On Wednesday, July 1st, Andrew Callos sold 15,000 shares of Cytokinetics stock. The shares were sold at an average price of $85.80, for a total value of $1,287,000.00.

Cytokinetics Stock Up 0.7%

Shares of CYTK stock opened at $71.93 on Thursday. The business’s fifty day moving average is $79.60 and its 200 day moving average is $72.41. The stock has a market cap of $8.95 billion, a price-to-earnings ratio of -9.96 and a beta of 0.36. Cytokinetics, Incorporated has a twelve month low of $47.22 and a twelve month high of $88.31.

Cytokinetics (NASDAQ:CYTK) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.63) by $0.13. The business had revenue of $28.62 million for the quarter, compared to analysts’ expectations of $17.59 million. Cytokinetics’s revenue for the quarter was down 57.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.12) earnings per share. Equities research analysts expect that Cytokinetics, Incorporated will post -6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cytokinetics

A number of institutional investors and hedge funds have recently bought and sold shares of CYTK. EverSource Wealth Advisors LLC lifted its holdings in shares of Cytokinetics by 723.7% in the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 673 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in Cytokinetics during the fourth quarter valued at $27,000. Kestra Advisory Services LLC bought a new stake in Cytokinetics in the 4th quarter valued at $29,000. Quarry LP purchased a new stake in Cytokinetics in the 3rd quarter worth $30,000. Finally, Advisory Services Network LLC purchased a new stake in Cytokinetics in the 3rd quarter worth $32,000.

Analyst Ratings Changes

A number of research firms have commented on CYTK. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytokinetics in a research report on Friday, July 17th. UBS Group upgraded Cytokinetics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $69.00 to $115.00 in a research note on Monday, June 29th. Citigroup reaffirmed a “market outperform” rating on shares of Cytokinetics in a report on Friday, August 7th. Wells Fargo & Company upped their price objective on Cytokinetics from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, Needham & Company LLC raised their target price on Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Eighteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Cytokinetics has an average rating of “Moderate Buy” and a consensus target price of $103.37.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: New Phase 3 progress in non-obstructive hypertrophic cardiomyopathy (HCM) expands aficamten’s potential market beyond obstructive HCM. Additional study findings also suggest benefits across both forms of the disease, strengthening the outlook for Cytokinetics’ lead cardiovascular program. Cytokinetics Reaches a Phase 3 First in Non-Obstructive HCM Can CYTK’s Aficamten Strengthen Its HCM Growth Prospects?
• Positive Sentiment: Evercore ISI and Goldman Sachs reaffirmed their Buy ratings on CYTK, while HC Wainwright also maintained its Buy recommendation. The repeated endorsements reinforce the favorable sell-side view of Cytokinetics’ pipeline and commercial potential. Evercore ISI Remains a Buy on Cytokinetics Goldman Sachs Reaffirms Its Buy Rating on Cytokinetics
• Neutral Sentiment: Management will participate in a Citi BioPharma investor conference on September 9. The event could provide pipeline or regulatory updates, but the announcement itself contained no new financial or clinical data. Cytokinetics to Participate in September Investor Conferences
• Negative Sentiment: CEO Robert Blum sold 7,500 shares for approximately $526,800, and director B. Lynne Parshall sold 5,000 shares for about $357,400. Both transactions were made under pre-arranged Rule 10b5-1 plans, which reduces their usefulness as signals of current management sentiment, but the sales may weigh modestly on investor confidence.
• Negative Sentiment: Cytokinetics remains unprofitable, with analysts expecting a substantial full-year loss. Its latest quarterly revenue also declined year over year, leaving the stock dependent on clinical and regulatory execution rather than current earnings.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.